December 1995

Allergic bronchopulmonary aspergillosis: an unusual complication of bronchial asthma

S F. Hussain
Aga Khan University

J A. Khan
Aga Khan University, javaid.khan@aku.edu

M A. Khan
Aga Khan University

Follow this and additional works at: https://ecommons.aku.edu/pakistan_fhs_mc_med_pulm_critcare

Part of the Critical Care Commons, and the Pulmonology Commons

Recommended Citation
Available at: https://ecommons.aku.edu/pakistan_fhs_mc_med_pulm_critcare/68
Allergic Bronchopulmonary Aspergillosis: An Unusual Complication of Bronchial Asthma

S. Fayyaz Hussain, Javaid A. Khan (Department of Medicine, The Aga Khan University Hospital, Karachi.)
M. Ata Khan (Department of Medicine, The Aga Khan University Hospital, Karachi.)

Introduction

Asthma is a common medical problem in Pakistan. Allergic Bronchopulmonary Aspergillosis (ABPA), an immune mediated disease, is an unusual complication of bronchial asthma which can result in bronchiectasis, pulmonary fibrosis, respiratory failure and death. Early diagnosis is important so that with proper therapy permanent lung damage can be prevented. First described in 1952, ABPA was thought to be a rare disorder, but with increased awareness amongst the physicians and better diagnostic techniques, cases are being recognized more frequently. The clinical features of ABPA (cough, fever, hemoptysis and lung infiltrates) are usually mistaken for pulmonary tuberculosis (TB). We present three cases in which failure to consider the diagnosis of ABPA resulted in repeated courses of anti-TB therapy and/or progressive lung damage and continued morbidity.

Case reports

Case 1: Recurrent hemoptysis and pulmonary infiltrates
A 19 year old male, asthmatic from childhood, developed fever, cough, hemoptysis and pulmonary infiltrate in 1987. He was treated for TB for nine months. In 1992, he again presented with fever, anorexia, cough, hemoptysis and patchy infiltration in left upper lobe (Figure 1a).
Sputum was negative for AFB but on clinical suspicion, he was restarted on quadruple anti-TB therapy in adequate doses. In addition, he continued to receive bronchodilators, inhaled steroids and intermittent courses of oral prednisolone. Six months later, while still on anti-TB drugs, he developed recurrence of symptoms with right pleuritic chest pain, fever, cough, wheeze and hemoptysis. Repeat chest x-ray showed infiltrates in right lung (Figure ib).
Sputum for AFB was negative. He had eosinophilia of 12% (WBC count 12600/dl) and grossly elevated serum IgE (>1000 iu/ml). Aspergillus antibodies were negative. A diagnosis of ABPA was made and prednisolone 30 mg daily was started. This resulted in rapid resolution of clinical and radiological features. Patient remains well on maintenance prednisolone at a dose of 7.5 mg daily.

**Case 2: Bilateral interstitial infiltrates and bronchiectasis**

A 24 year old male, asthmatic for four years, presented with high grade fever, cough with purulent sputum and right sided chest pain. He had two similar episodes during the last one year. Bilateral widespread rhonchi and crepitation were found on chest examination. Chest x-ray showed bilateral interstitial infiltrates and bronchiectatic changes. White cell count was 12700/dl with 33% eosinophils. Sputa for AFB were negative. Patient improved partially with a course of Amoxicillin-Clavulanic Acid, bronchodilators and physiotherapy but continued to be wheezy and dyspnoeic. Serum IgE was elevated above 1000 IU/ml.
CT scan of the chest (Figure 2) revealed mucous impaction in the bronchi and central bronchiectasis. He made a good response to oral steroid therapy.

**Case 3: Migratory infiltrates and marked eosinophilia**

This 28 year old lady gave two years history of recurrent cough, fever and wheeze. Symptoms improved temporarily with the use of antibiotics and bronchodilators but recurred on stopping therapy. She presented with relapse of her symptoms and was found to have bilateral wheeze. White cell count was 24,800/di with marked eosinophilia of 60%. Chest x-ray showed infiltrates in left upper and right middle zones. Her previous eosinophil counts varied from 40-60% and x-rays showed fleeting pulmonary infiltrates. Serum IgE was elevated at 970 IU/ml. She made a rapid clinical and radiological response to oral steroid therapy and remained well one year after discharge.
Discussion

Aspergillus fungus is widely distributed throughout the world and can involve the lung through a number of diverse mechanisms. A. fumigatus is the most common pathogenic species, but other species such as A. niger, A. flavus and A. terreus are also pathogenic in humans. Allergic broncho pulmonary aspergillus (ABPA) is primarily an immune mediated disorder. It develops when aspergillus colonizes the airways of a susceptible host and produces antigens. There is no tissue invasion by the fungus. Type I (IgE mediated immediate hypersensitivity), Type III (IgG mediated immune complex) and Type IV (cell mediated delayed hypersensitivity) responses have all been implicated in the disease process. These immune responses result in bronchospasm, increased permeability of bronchial mucosa, pulmonary and blood eosinophilia, chronic inflammation and bronchial destruction, bronchiectasis and pulmonary fibrosis. Most patients with ABPA are very atopic and have asthma. The peak incidence of ABPA is in the third and fourth decade of life. Other allergic symptoms, such as rhinitis, conjunctivitis, urticaria, eczema, food or drug allergy may also be present. In corticosteroid dependent asthmatics prevalence of ABPA was found to be 7-14% in North America and 15-22% in Great Britain. In India, the prevalence of antibodies to Aspergillus among asthmatics was found to be 20% by ELISA method. The other conditions where ABPA occurs in up to 10% of patients is cystic fibrosis. The clinical features include cough, hemoptysis, expectoration of mucus plugs, dyspnoea, fever, malaise, anorexia and pleuritic chest pain in an asthmatic patient. Most of these features are easily confused as TB and result in repeated courses of prolonged anti-TB therapy. Physician's awareness for ABPA is very low which results in delayed diagnosis and permanent lung damage. There is no single pathognomonic test for ABPA but the diagnosis can be made by following Rosenberg and Patterson’s criteria (Table). However, the serological markers may be absent during remission or when the patient is on corticosteroids. The patient may be followed for several years before all the diagnostic criteria can be fulfilled. Species of aspergillus other than A. fumigatus and fungi other than aspergillus have also been reported to cause similar disease and in these cases the serological markers for A. fumigatus would be negative. Serial chest radiographs reveal fleeting pulmonary infiltrates usually in the upper lobes. Tramline, parallel line and ring shadows represent thickened bronchial walls. The typical branching toothpaste and gloved finger shadows are due to mucous impaction. Massive consolidation may be seen. Atelectasis and pulmonary, fibrosis is less common. Bronchography has been the gold standard for the diagnosis of bronchiectasis but high resolution CT scan is equally sensitive for detection of bronchial wall changes. The course of ABPA is marked by recurrent episodes of reversible bronchial obstruction. Without early diagnosis and treatment, central bronchiectasis, pulmonary fibrosis, respiratory failure and death may occur. Some of the other conditions, characterised by pulmonary infiltrates, peripheral eosinophilia and elevated serum IgE level, which need to be differentiated from ABPA are Loeffler’s syndrome, tropical pulmonary eosinophilia, eosinophilic pneumonia, hypereosinophilic syndrome and Churg Strauss syndrome. Systemic corticosteroids control acute exacerbation, prevent permanent lung damage and is the treatment of choice. Usual starting dose of 0.5 mg/kg/day is given for 2-3 weeks and then tapered gradually over the next 6 months. High dose inhaled steroids can be beneficial and may help to diminish the dose or duration of oral steroids. Anti-fungal therapy had been ineffective in the therapy of ABPA but recent studies with newer agents such as Itraconazole appear promising. Diagnosis of ABPA requires a high index of suspicion. It should be considered in asthmatics who develop systemic symptoms, fleeting pulmonary shadows, eosinophilia and grossly elevated serum IgE levels. Pulmonary TB should be ruled out by sputum examination and other diseases with pulmonary
infiltrates and eosinophilia need to be excluded. Early diagnosis and steroid therapy are crucial to prevent irreversible lung damage and respiratory failure.

References